LIfT BioSciences Attracts Super Angels and Institutions in Further Round of Funding

Home > investors > LIfT BioSciences Attracts Super Angels and Institutions in Further Round of Funding

Biotech LIfT BioSciences has announced a further major investment into the company in its mission to develop the first curative and affordable cell therapy for all solid tumours. Investors in this latest round included Jonathan Milner, a leading biotech ‘super-angel’ investor and earlier stage investor in LIfT, Kizoo Technology Ventures, a leading early-stage investor in breakthrough technologies and Downing Ventures, a leading London-based investor.

This latest investment should provide added comfort for Shadow Foundr investors who bought into the company on a previous round.

“LIfT have developed and patented the most promising cancer therapy I have come across to date, with huge potential to transform the lives of cancer patients with a diverse range of solid tumours. I am super excited about being a part of the LIfT journey to bring this exciting technology to market and to start saving lives” said Jonathan Milner.

“We are very proud to support LIfT’s game-changing platform that breaks with the old-fashioned single-target approach and welcome Downing Ventures as a new investor”, said Patrick Burgermeister, Partner of Kizoo, “Downing is happy to be supporting the exciting and novel therapeutic treatment that LIfT is developing. This technology has the capability to make a fundamental increase in the options available in cancer treatment” said Will Brooks, Investment Director at Downing Ventures.

The company’s first product, N-LIfT (Neutrophil Only Leukocyte Infusion Therapy), works by effectively transferring the innate immunity that some exceptional people naturally have in their blood to cancer patients. The treatment is expected to give cancer patients up to 20 times the cancer killing ability they had been exhibiting themselves.

“Rapidly dividing cancer cells are able to adapt whereas targeted therapies are not,” said Alex Blyth, CEO of LIfT BioSciences. “This is a major flaw with current treatment options for patients, as their cancers are often only temporarily slowed before mutating and returning aggressively. Until now the only other approach has been broad chemotherapies that are essentially only slightly more toxic to cancer cells than healthy cells.”

“Whereas N-LIfT is a smart living therapy that selectively destroys any cancer cell we throw at it, regardless of type, mutational status or whether they are hot or cold tumours. N-LIfT also has the potential to improve the performance of other therapies that struggle with solid tumours and cold (non-inflamed) tumour environments. We believe that N-LIfT has the potential to be a paradigm-shifting change in how we treat cancer.”

This latest investment will help LIfT BioSciences further develop its manufacturing technology to cost-effectively produce N-LIfT, and fund pre-clinical in-vivo work.

LIfT BioSciences is looking to demonstrate in-vivo superiority over standard of care in Pancreatic Ductal Adenocarcinoma (PDAC), Non-Small Cell Lung Cancer (NSCLC) and Hepatocellular Carcinoma (HCC). Additional venture capital and private family wealth funds are being invited to join the investment syndicate, to fund early clinical trials and manufacturing scale-up.

To see more opportunities in the BioTech/MedTech sectors, please click here.

Share this

Top